VCYT Veracyte Inc

Price (delayed)

$22.74

Market cap

$1.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.67

Enterprise value

$1.48B

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other ...

Highlights
Veracyte's revenue has surged by 104% YoY and by 14% QoQ
Veracyte's gross profit has surged by 102% YoY and by 14% QoQ
The debt has grown by 3.6% YoY but it has contracted by 2.3% from the previous quarter
The company's quick ratio has shrunk by 69% YoY

Key stats

What are the main financial stats of VCYT
Market
Shares outstanding
71.45M
Market cap
$1.62B
Enterprise value
$1.48B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.49
Price to sales (P/S)
6.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.9
Earnings
Revenue
$250.59M
EBIT
-$50.39M
EBITDA
-$24.83M
Free cash flow
-$6.57M
Per share
EPS
-$0.67
Free cash flow per share
-$0.09
Book value per share
$15.24
Revenue per share
$3.52
TBVPS
$3.83
Balance sheet
Total assets
$1.17B
Total liabilities
$88.4M
Debt
$18.41M
Equity
$1.09B
Working capital
$175.94M
Liquidity
Debt to equity
0.02
Current ratio
3.81
Quick ratio
3.31
Net debt/EBITDA
5.88
Margins
EBITDA margin
-9.9%
Gross margin
65.8%
Net margin
-19.2%
Operating margin
-20.6%
Efficiency
Return on assets
-4.2%
Return on equity
-4.5%
Return on invested capital
-83.4%
Return on capital employed
-4.5%
Return on sales
-20.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
4.22%
1 week
33.76%
1 month
34.24%
1 year
-43.99%
YTD
-44.81%
QTD
-17.52%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$250.59M
Gross profit
$164.88M
Operating income
-$51.74M
Net income
-$48.16M
Gross margin
65.8%
Net margin
-19.2%
Veracyte's revenue has surged by 104% YoY and by 14% QoQ
Veracyte's gross profit has surged by 102% YoY and by 14% QoQ
The net margin has soared by 64% YoY and by 44% from the previous quarter
The operating margin has soared by 63% YoY and by 45% from the previous quarter

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
P/E
N/A
P/B
1.49
P/S
6.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.9
The EPS has increased by 40% since the previous quarter and by 39% year-on-year
The P/B is 73% below the 5-year quarterly average of 5.6 and 40% below the last 4 quarters average of 2.5
The equity has grown by 11% YoY
Veracyte's revenue has surged by 104% YoY and by 14% QoQ
The P/S is 53% below the last 4 quarters average of 13.8 and 39% below the 5-year quarterly average of 10.6

Efficiency

How efficient is Veracyte business performance
The ROA has soared by 65% YoY and by 38% from the previous quarter
The company's return on equity has surged by 65% YoY and by 38% QoQ
The return on sales has surged by 64% year-on-year and by 46% since the previous quarter
VCYT's return on invested capital is up by 46% year-on-year and by 42% since the previous quarter

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The total liabilities has soared by 74% YoY but it has contracted by 3.2% from the previous quarter
The company's quick ratio has shrunk by 69% YoY
The debt is 98% less than the equity
The equity has grown by 11% YoY
The debt has grown by 3.6% YoY but it has contracted by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.